Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.
In order to evaluate the potentiating effect of cefuroxime on tobramycin nephrotoxicity 21 immunocompromised patients with suspected septicaemia were randomized to treatment with either tobramycin + cefuroxime or tobramycin + penicillin G. 51Chromium-EDTA clearance, serum creatinine, serum beta 2-microglobulin, urinary, alanine aminopeptidase, urinary N-acetyl-beta-D-glucosaminidase and urinary beta 2-microglobulin were measured during a nine day course of the antibiotic combinations. Enzymuria and a small but significant decrease of 51Chromium-EDTA clearance of equal magnitude in both treatment groups occurred. However the results cannot be extrapolated to other doses and treatment times than used in the study.
D002444:Cefuroxime / Q000009:adverse effects*; D002511:Cephalosporins / Q000009:adverse effects*; D002860:Chromium Radioisotopes; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005919:Glomerular Filtration Rate; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D007677:Kidney Function Tests; D010400:Penicillin G / Q000009:adverse effects*; D011446:Prospective Studies; D011897:Random Allocation; D014031:Tobramycin / Q000009:adverse effects*; D001613:beta 2-Microglobulin / Q000378:metabolism
D002511:Cephalosporins; D002860:Chromium Radioisotopes; D001613:beta 2-Microglobulin; D002444:Cefuroxime; D010400:Penicillin G; D014031:Tobramycin